Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Longitude takes a spin with Cydan

Why Longitude funded Cydan's latest spinout to makeover an Ipsen asset

Jennie Walters, Staff Writer
January 5, 2019 12:39 AM UTC

Longitude Capital's first foray into a Cydan Development Inc. spinout came Thursday when Cydan launched Tiburio Therapeutics Inc. to repurpose TBR-760 (formerly BIM-23A760) from Ipsen Group (Euronext:IPN; Pink:IPSEY), eight years after the compound's false start in acromegaly.

Longitude's Sandip Agarwala told BioCentury the mechanism of action that tripped up BIM-23A760 in acromegaly gives the dopamine-somatostatin chimeric molecule significant potential in non-functioning pituitary adenoma (NFPA)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cydan II Inc.

Ipsen Group

Longitude Capital Management